Target Audience (click to view)
This activity is designed to meet the needs of physicians.
Learning Objectives(click to view)
Upon completion of the educational activity, participants should be able to:
- Discuss the findings—and their implications—of a systematic review that identified and analyzed studies of patient preferences in patients with type 2 diabetes not on insulin.
- Explain what needs still exist in this area for future research to focus on.
Method of Participation(click to view)
Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.akhcme.com/pwjuly3. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at firstname.lastname@example.org.
Credit Available(click to view)
CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support(click to view)
There is no commercial support for this activity.
Disclosures(click to view)
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use & Investigational Product(click to view)
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer(click to view)
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Faculty & Credentials(click to view)
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN- CE Director of Accreditation
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
AKH planners and reviewers have no relevant financial relationships to disclose.
Complete the Post Test(click to view)
As type 2 diabetes has become a more manageable chronic condition, there has been a recent push to implement patient-centered care approaches for those with the disease. “Studies have shown that type 2 diabetes is often poorly controlled, and adherence to insulin and non-insulin medications is frequently suboptimal,” explains Tanjala S. Purnell, PhD, MPH. “This can increase patients’ risk for developing cardiovascular disease, chronic kidney disease, and other health problems. Understanding why patients prefer certain treatments for their diabetes is an important and necessary part of achieving patient-centered care.”
The issue of treatment preference in type 2 diabetes is complex because there is a wide range of medication options. With these options comes consideration of drug-related benefits, harms, and burden as well as the likelihood or uncertainty of treatment-related outcomes. When measuring patient preferences, Dr. Purnell says it is important to determine how patients value specific outcomes, such as the importance of weight maintenance or glycemic control. It is also important to measure how patients choose between treatment options and how their choices are influenced by particular attributes of treatment.
A Systematic Review
Although patient preferences are deemed important by major diabetes professional societies, little is known about how these preferences influence treatment for type 2 diabetes. To address this research gap, Dr. Purnell and colleagues conducted a systematic review that identified and analyzed studies of patient preferences in patients with type 2 diabetes not on insulin. The study, published in Diabetes Care, reviewed several databases for articles in which patient preferences for diabetes medication treatment were assessed.
For the analysis, many important attributes were examined in clinical studies when assessing patient preferences for using non-insulin diabetes medications (Table 1). According to the study results, weight loss, weight control, and glycemic control were identified as key attributes of diabetes treatment that drove patient preferences when compared with treatment burden and side effects. The most common attribute comparisons were weight loss/control and glycemic control versus treatment-related burden and side effects (Table 2).
The study also found that treatment burden—which referred to factors such as administration, frequency, and cost—was another key attribute of patient preferences, although evidence on this component was sparse. “Concerns about gastrointestinal side effects were ranked as more important than concerns about hypoglycemia by patients within the studies assessed in our systemic review,” adds Dr. Purnell. “Avoidance of weight gain was also cited by patients as being an important driver in the decisions they made when they were considering either taking or avoiding specific non-insulin drugs.”
According to Dr. Purnell, the study findings highlight the relative importance of factors that are likely to influence treatment decisions. “Patients who understand the benefits and risks of non-insulin medications are more likely to adhere to their treatment regimen,” Dr. Purnell says. “Clinicians should take time to discuss with their patients how they view potential weight loss and weight control, glycemic control, and gastrointestinal side effects before they initiate therapies and throughout the duration of care.”
Increasing awareness about the importance of factors that influence patient preferences may have a significant impact on medication outcomes. For example, clinicians may believe that a certain drug is ineffective when the reality is that patients are poorly adhering to that medication because of its side effects. In some circumstances, side effects like weight gain can be avoided by switching medications. Dr. Purnell says clinicians should discuss the factors that patients value with treatment and recognize the factors that can negatively affect drug adherence.
More Research Needed
Beyond having clinicians consider the factors identified in the study, Dr. Purnell says greater efforts are needed to evaluate patient preferences in future research. With more research, there is hope that experts will develop evidence-based guidelines for improving how patient preferences are evaluated and incorporated into routine care. “Consideration of patient preferences in decisions about non-insulin medications is an important and necessary step toward individualizing care and encouraging patient-centered decisions,” says Dr. Purnell. The next step would be to develop and implement clinical decision support tools that incorporate patient preferences in the treatment of type 2 diabetes.
The study by Dr. Purnell and colleagues also notes that efforts are needed to develop a widely accepted definition of patient preferences and how they should be measured. This information could then be incorporated into clinical guidelines. Dr. Purnell believes that her study team’s findings can serve as a starting point for such recommendations. These efforts may ultimately improve patient adherence to therapies for type 2 diabetes and optimize outcomes for those living with the disease.
Readings & Resources (click to view)
Purnell TS, Joy S, Little E, Bridges JF, Maruther N. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37:2055-2062. Available at: http://care.diabetesjournals.org/content/37/7/2055.full.
Joy SM, Little E, Maruthur NM, Purnell TS, Bridges JF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31:877-892.
Brown SE, Meltzer DO, Chin MH, Huang ES. Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. J Am Geriatr Soc. 2008;56:1183-1190.
Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416-424.